Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster COVID-19 vaccination response in kidney transplant recipients
ACTRN12622001106729Phase 4Completed
- Sponsor
- Martin Kacer
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Martin Kacer. Primary endpoint: Positive humoral response after vaccination. Started Sep 2021; status: completed.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12622001106729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001106729.